StreetInsider.com News Articles

RedHill explores opaganib for ebola outbreak response

Tue, 02 Jun 2026 08:00:56 -0400

RedHill Biopharma Ltd. (NASDAQ: RDHL) announced it is discussing potential collaborations to advance its investigational drug opaganib for Ebola virus disease treatment, including with the World Health Organization's SOLIDARITY CORE clinical trial platform.

The discussions come amid an ongoing Ebola outbreak involving the rare Bundibugyo ebolavirus sub-type, for which no approved medications or vaccines exist. The WHO has indicated the current outbreak is outpacing response efforts.

Opaganib demonstrated a 70.2% mortality reduction when added to standard care in a Phase 3 COVID-19 trial, according to data published in Microorganisms. The treatment group showed 6.98% mortality compared to 23.4% in the placebo group

RedHill explores opaganib for ebola outbreak response

Tue, 02 Jun 2026 08:00:56 -0400

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Tue, 02 Jun 2026 08:00:00 -0400

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib¹, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform

Opaganib EVD rationale (analogous to EVD treatment pathway):

Phase 3 clinical antiviral activity (severe COVID-19) showing²:
- 70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo +

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Tue, 02 Jun 2026 08:00:00 -0400

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib¹, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform
Opaganib EVD rationale (analogous to EVD treatment pathway):
Phase 3 clinical antiviral activity (severe COVID-19) showing²:
70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo +

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Tue, 02 Jun 2026 08:00:00 -0400

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib¹, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform
Opaganib EVD rationale (analogous to EVD treatment pathway):
Phase 3 clinical antiviral activity (severe COVID-19) showing²:
70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo +

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Tue, 02 Jun 2026 08:00:00 -0400

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib¹, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform
Opaganib EVD rationale (analogous to EVD treatment pathway):
Phase 3 clinical antiviral activity (severe COVID-19) showing²:
70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo +

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Tue, 02 Jun 2026 08:00:00 -0400

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib¹, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform
Opaganib EVD rationale (analogous to EVD treatment pathway):
Phase 3 clinical antiviral activity (severe COVID-19) showing²:
70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo +

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Tue, 02 Jun 2026 08:00:00 -0400

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib¹, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform
Opaganib EVD rationale (analogous to EVD treatment pathway):
Phase 3 clinical antiviral activity (severe COVID-19) showing²:
70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo +

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Tue, 02 Jun 2026 08:00:00 -0400

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib¹, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform
Opaganib EVD rationale (analogous to EVD treatment pathway):
Phase 3 clinical antiviral activity (severe COVID-19) showing²:
70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo +

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Tue, 02 Jun 2026 08:00:00 -0400

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib¹, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform
Opaganib EVD rationale (analogous to EVD treatment pathway):
Phase 3 clinical antiviral activity (severe COVID-19) showing²:
70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo +

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Tue, 02 Jun 2026 08:00:00 -0400

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib¹, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform
Opaganib EVD rationale (analogous to EVD treatment pathway):
Phase 3 clinical antiviral activity (severe COVID-19) showing²:
70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo +

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Tue, 02 Jun 2026 08:00:00 -0400

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib¹, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform
Opaganib EVD rationale (analogous to EVD treatment pathway):
Phase 3 clinical antiviral activity (severe COVID-19) showing²:
70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo +

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Tue, 02 Jun 2026 08:00:00 -0400

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib¹, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform
Opaganib EVD rationale (analogous to EVD treatment pathway):
Phase 3 clinical antiviral activity (severe COVID-19) showing²:
70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo +

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Tue, 02 Jun 2026 08:00:00 -0400

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib¹, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform
Opaganib EVD rationale (analogous to EVD treatment pathway):
Phase 3 clinical antiviral activity (severe COVID-19) showing²:
70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo +

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Tue, 02 Jun 2026 08:00:00 -0400

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib¹, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform
Opaganib EVD rationale (analogous to EVD treatment pathway):
Phase 3 clinical antiviral activity (severe COVID-19) showing²:
70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo +

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Tue, 02 Jun 2026 08:00:00 -0400

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib¹, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform
Opaganib EVD rationale (analogous to EVD treatment pathway):
Phase 3 clinical antiviral activity (severe COVID-19) showing²:
70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo +

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Tue, 02 Jun 2026 08:00:00 -0400

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib¹, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform
Opaganib EVD rationale (analogous to EVD treatment pathway):
Phase 3 clinical antiviral activity (severe COVID-19) showing²:
70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo +

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Tue, 02 Jun 2026 08:00:00 -0400

Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib¹, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform
Opaganib EVD rationale (analogous to EVD treatment pathway):
Phase 3 clinical antiviral activity (severe COVID-19) showing²:
70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo +

RedHill's RHB-204 shows comparable efficacy to RHB-104 in lab tests

Thu, 30 Apr 2026 07:03:47 -0400

RedHill Biopharma Ltd. (NASDAQ: RDHL) announced that its experimental drug RHB-204 demonstrated comparable efficacy to RHB-104 in killing Mycobacterium avium subspecies paratuberculosis (MAP) in laboratory testing. The results were achieved using lower doses of two active ingredients compared to RHB-104, according to the company's statement.
RHB-204 is designed as an optimized formulation of RHB-104 for treating Crohn's disease. The drug contains clarithromycin, rifabutin and clofazimine in a fixed-dose oral capsule. RedHill reported that the comparable results were achieved in both spot and phage assays across several MAP strains.
"The demonstration of RHB-204's comparability to RHB-104 is an important step forward in the

RedHill's RHB-204 shows comparable efficacy to RHB-104 in lab tests

Thu, 30 Apr 2026 07:03:47 -0400

RedHill Biopharma Ltd. (NASDAQ: RDHL) announced that its experimental drug RHB-204 demonstrated comparable efficacy to RHB-104 in killing Mycobacterium avium subspecies paratuberculosis (MAP) in laboratory testing. The results were achieved using lower doses of two active ingredients compared to RHB-104, according to the company's statement.
RHB-204 is designed as an optimized formulation of RHB-104 for treating Crohn's disease. The drug contains clarithromycin, rifabutin and clofazimine in a fixed-dose oral capsule. RedHill reported that the comparable results were achieved in both spot and phage assays across several MAP strains.
"The demonstration of RHB-204's comparability to RHB-104 is an important step forward in the

RedHill's RHB-204 shows comparable efficacy to RHB-104 in lab tests

Thu, 30 Apr 2026 07:03:47 -0400

RedHill Biopharma Ltd. (NASDAQ: RDHL) announced that its experimental drug RHB-204 demonstrated comparable efficacy to RHB-104 in killing Mycobacterium avium subspecies paratuberculosis (MAP) in laboratory testing. The results were achieved using lower doses of two active ingredients compared to RHB-104, according to the company's statement.
RHB-204 is designed as an optimized formulation of RHB-104 for treating Crohn's disease. The drug contains clarithromycin, rifabutin and clofazimine in a fixed-dose oral capsule. RedHill reported that the comparable results were achieved in both spot and phage assays across several MAP strains.
"The demonstration of RHB-204's comparability to RHB-104 is an important step forward in the

RedHill's RHB-204 shows comparable efficacy to RHB-104 in lab tests

Thu, 30 Apr 2026 07:03:47 -0400

RedHill Biopharma Ltd. (NASDAQ: RDHL) announced that its experimental drug RHB-204 demonstrated comparable efficacy to RHB-104 in killing Mycobacterium avium subspecies paratuberculosis (MAP) in laboratory testing. The results were achieved using lower doses of two active ingredients compared to RHB-104, according to the company's statement.
RHB-204 is designed as an optimized formulation of RHB-104 for treating Crohn's disease. The drug contains clarithromycin, rifabutin and clofazimine in a fixed-dose oral capsule. RedHill reported that the comparable results were achieved in both spot and phage assays across several MAP strains.
"The demonstration of RHB-204's comparability to RHB-104 is an important step forward in the

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

Thu, 30 Apr 2026 07:00:00 -0400

RHB-204¹ is a next-generation optimized formulation of RedHill's oral RHB-104², designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium avium subspecies paratuberculosis (MAP)-targeted therapeutic approach for Crohn's disease (CD)
In its positive Phase 3 study, RHB-104 met the primary and key secondary endpoints with statistical significance, showing RHB-104 plus standard of care (SoC) to be 64% more effective than SoC alone, in treating CD compared to the placebo (standard of care only) group (p = 0.0048)³
New RHB-204 in vitro data, from both spot and phage assays, demonstrated comparable MAP killing to RHB-104⁴. Importantly,

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

Thu, 30 Apr 2026 07:00:00 -0400

RHB-204¹ is a next-generation optimized formulation of RedHill's oral RHB-104², designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium avium subspecies paratuberculosis (MAP)-targeted therapeutic approach for Crohn's disease (CD)
In its positive Phase 3 study, RHB-104 met the primary and key secondary endpoints with statistical significance, showing RHB-104 plus standard of care (SoC) to be 64% more effective than SoC alone, in treating CD compared to the placebo (standard of care only) group (p = 0.0048)³
New RHB-204 in vitro data, from both spot and phage assays, demonstrated comparable MAP killing to RHB-104⁴. Importantly,

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

Thu, 30 Apr 2026 07:00:00 -0400

RHB-204¹ is a next-generation optimized formulation of RedHill's oral RHB-104², designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium avium subspecies paratuberculosis (MAP)-targeted therapeutic approach for Crohn's disease (CD)
In its positive Phase 3 study, RHB-104 met the primary and key secondary endpoints with statistical significance, showing RHB-104 plus standard of care (SoC) to be 64% more effective than SoC alone, in treating CD compared to the placebo (standard of care only) group (p = 0.0048)³
New RHB-204 in vitro data, from both spot and phage assays, demonstrated comparable MAP killing to RHB-104⁴. Importantly,